GlassScriptPhysician profile
Jonathan Daniel Casciano
NPI 1518182526
$4,075.35
in general payments reported to CMS, 2019-2025
30 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $268 · 2021: $599 · 2022: $522 · 2023: $625 · 2024: $755 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Entertainment: $92.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.08 |
| Entertainment | $92.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506.56 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Alcon Vision LLC | $430.01 | 2019-2025 | Argos, Eysuvis, Clareon |
| Sun Pharmaceutical Industries INC. | $420.09 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $295.43 | 2019-2023 | |
| Allergan, INC. | $282.63 | 2019-2022 | |
| Ocular Therapeutix, INC. | $275.38 | 2023-2025 | Dextenza |
| Oyster Point Pharma, INC. | $268.47 | 2022-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $219.23 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $185.00 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Ivantis, INC | $166.74 | 2019-2021 | |
| Optos, INC. | $136.45 | 2021-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $126.13 | 2019 | |
| Kala Pharmaceuticals, INC. | $112.63 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.44 | 2019-2021 | |
| Thea Pharma INC. | $64.32 | 2023-2025 | Iyuzeh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $63.98 | 2020-2023 | Flarex |
| Aerie Pharmaceuticals, INC. | $62.49 | 2019-2021 | |
| Glaukos Corporation | $62.16 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Carl Zeiss Meditec USA, INC. | $52.59 | 2021 | |
| Sight Sciences, INC. | $52.59 | 2021-2022 | |
| Amgen INC. | $46.52 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $29.58 | 2021 | |
| Omeros Corporation | $25.27 | 2019 | |
| New World Medical,INC. | $24.84 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $23.23 | 2024 | Xdemvy |
| Astellas Pharma US INC | $21.30 | 2024 | Izervay |
| Horizon Therapeutics Plc | $18.48 | 2023 | |
| Coopervision INC. | $15.42 | 2023 | Biofinity Contact Lens |
| Eyepoint US, INC. | $12.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Casciano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.